文献速递肝病

因子VIII/蛋白C比值可独立预测肝相关事件,但不提示ACLD患者存在高凝状态

Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD.
PubMed 文献 · J Hepatol · 2022-01-20

在576例晚期慢性肝病(ACLD)患者中,因子VIII/蛋白C比值(FVIII/PC)随临床分期、HVPG和MELD评分分层显著升高,并独立预测失代偿/肝相关死亡和ACLF。在142例TM-TGA队列中,FVIII/PC与内源性凝血酶潜力仅弱相关且校正肝病严重程度后消失,与出血或血栓事件无关。

要点

  • FVIII/PC随ACLD临床分期、HVPG和MELD评分分层显著升高(p均<0.001)。
  • FVIII/PC独立预测失代偿/肝相关死亡(aHR 1.06;95%CI 1.01-1.11;p=0.013)。
  • FVIII/PC与出血(p=0.272)或血栓事件(p=0.269)无关,不反映凝血状态。

核心结论

  • FVIII/PC可提供关于肝性失代偿/死亡和ACLF的预后信息,独立于已有预后指标。
  • 但这不是高凝状态驱动疾病进展的证据,因为FVIII/PC与凝血酶生成的相关性被肝病严重程度混杂,且FVIII/PC与血栓形成无关。
  • 因此FVIII/PC不反映凝血,既往关于FVIII/PC的研究结果需要重新解读。

研究设计与样本

  • 预后队列纳入576例有晚期慢性肝病证据的患者(肝硬度测量≥10 kPa和/或HVPG≥6 mmHg)。
  • TM-TGA队列患者(n=142)招募自前瞻性VIenna CIrrhosis Study(VICIS:NCT03267615)。
  • 研究评估FVIII/PC的预后价值,以及其是否反映高凝状态(通过血栓调节蛋白修饰的凝血酶生成试验[TM-TGA]评估)或出血/血栓事件风险。

主要发现

  • FVIII/PC随临床分期(p<0.001)、HVPG(p<0.001)和MELD评分(p<0.001)分层显著升高。
  • FVIII/PC独立与失代偿/肝相关死亡相关(校正风险比1.06;95%CI 1.01-1.11;p=0.013),即使经过多变量校正后仍显著。
  • 在失代偿期肝硬化患者中,FVIII/PC与ACLF发生相关(校正风险比1.10;95%CI 1.02-1.19;p=0.015)。
  • FVIII/PC与内源性凝血酶潜力呈弱正相关(Spearman's ρ=0.255;p=0.002),但校正肝病严重程度后该关联消失。
  • FVIII/PC与出血事件发生(p=0.272)或血栓事件发生(p=0.269)无关。

临床怎么用

  • 作者认为FVIII/PC可提供关于肝性失代偿/死亡和ACLF的预后信息,独立于已有预后指标。
  • 作者指出FVIII/PC不反映凝血,既往关于FVIII/PC的研究结果需要重新解读。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: It has been suggested that the ratio of procoagulant factor VIII to anticoagulant protein C (FVIII/PC) reflects the hemostatic equilibrium. Moreover, FVIII/PC predicted decompensation/death in a small study not accounting for portal hypertension severity. We investigated (i) the prognostic value of FVIII/PC (outcome-cohort) and (ii) whether FVIII/PC reflects the hypercoagulable state (assessed by thrombomodulin-modified thrombin generation assay [TM-TGA]) or the risk of bleeding/thrombotic events in patients undergoing hepatic venous pressure gradient (HVPG) measurement during follow-up. METHODS: (i) The outcome-cohort comprised 576 patients with evidence of advanced chronic liver disease (liver stiffness measurement ≥10 kPa and/or HVPG ≥6 mmHg). (ii) TM-TGA-cohort patients (n = 142) were recruited from the prospective VIenna CIrrhosis Study (VICIS: NCT03267615). RESULTS: (i) FVIII/PC significantly increased across clinical stages (p <0.001) as well as HVPG (p <0.001) and MELD score (p <0.001) strata and remained independently associated with decompensation/liver-related death (adjusted hazard ratio 1.06; 95% CI 1.01-1.11; p = 0.013), even after multivariable adjustment. It was also associated with acute-on-chronic liver failure (ACLF) development (adjusted hazard ratio 1.10; 95% CI 1.02-1.19; p = 0.015) in patients with decompensated cirrhosis. (ii) FVIII/PC showed a weak positive correlation with endogenous thrombin potential (Spearman's ρ = 0.255; p = 0.002), but this association disappeared after adjusting for the severity of liver disease. FVIII/PC was not associated with the development of bleeding (p = 0.272) or thrombotic events (p = 0.269). However, FVIII/PC correlated with biomarkers of different pathophysiological mechanisms that promote liver disease progression. CONCLUSION: FVIII/PC provides prognostic information regarding hepatic decompensation/death and ACLF, independently of established prognostic indicators. However, this is not evidence that hypercoagulability drives disease progression, as the correlation between FVIII/PC and thrombin generation is confounded by liver disease severity and FVIII/PC was not associated with thrombosis. Therefore, FVIII/PC does not reflect coagulation and results from previous studies on FVIII/PC require re-interpretation. CLINICAL TRIAL NUMBER: NCT03267615 (in part). LAY SUMMARY: A balanced coagulation system is essential for preventing bleeding episodes and blood clot formation (thrombosis). Blood of patients with advanced liver disease may have increased coagulation potential, possibly promoting the worsening of liver disease via thrombosis in the blood vessels of the liver. The ratio between the results of 2 blood tests (procoagulant factor VIII to anticoagulant protein C) has been suggested to reflect these increases in coagulation potential. Our study demonstrates, on the one hand, that this ratio is a versatile predictor of the development of complications of cirrhosis, yet on the other hand, that it is unrelated to coagulation.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Scheiner B, Balcar L, Nussbaumer RJ, et al. Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD. J Hepatol. 2022. PMID: 35066090. doi:10.1016/j.jhep.2021.12.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。